Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005;9(6):R653-61.
doi: 10.1186/cc3815. Epub 2005 Oct 11.

Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation

Affiliations
Clinical Trial

Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation

Hidehiko Kushi et al. Crit Care. 2005.

Abstract

Introduction: The objective of this study was to clarify the efficacy and mechanism of action of direct hemoperfusion with an immobilized polymyxin B fiber column (DHP-PMX) in patients with acute lung injury or acute respiratory distress syndrome caused by sepsis.

Method: Thirty-six patients with sepsis were included. In each patient a thermodilution catheter was inserted, and the oxygen delivery index and oxygen consumption index were measured. DHP-PMX was performed in patients with a normal oxygen delivery index and oxygen consumption index (> 500 ml/minute per m2 and > 120 ml/minute per m2, respectively). The Acute Physiology and Chronic Health Evaluation II score was used as an index of the severity of sepsis, and survival was assessed after 1 month. The humoral mediators measured were the chemokine IL-8, plasminogen activator inhibitor-1, and neutrophil elastase (NE). These mediators were measured before DHP-PMX treatment, and at 24, 48, and 78 hours after the start of treatment. The arterial oxygen tension (PaO2)/fractional inspired oxygen (FiO2) ratio was measured before DHP-PMX treatment and at 24, 48, 72, 92, and 120 hours after the start of treatment.

Results: All patients remained alive after 1 month. Before DHP-PMX treatment, the Acute Physiology and Chronic Health Evaluation II score was 24 +/- 2.0, the IL-8 level was 54 +/- 15.8 pg/ml, plasminogen activator inhibitor-1 was 133 +/- 28.1 ng/ml, and NE was 418 +/- 72.1 mug/l. These three humoral mediators began to decrease from 24 hours after DHP-PMX treatment, and the decline became significant from 48 hours onward. The PaO2/FiO2 ratio was 244 +/- 26.3 before DHP-PMX treatment but improved significantly from 96 hours onward. There were significant negative correlations between the PaO2/FiO2 ratio and blood levels of NE and IL-8.

Conclusion: The mechanism of action of DHP-PMX is still not fully understood, but we report the following findings. The mean blood levels of plasminogen activator inhibitor-1, NE, and IL-8 were significantly decreased from 48 hours after DHP-PMX treatment. The mean PaO2/FiO2 ratio was significantly improved from 96 hours after DHP-PMX treatment. Improvement in the PaO2/FiO2 ratio appeared to be related to the decreases in blood NE and IL-8 levels.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in PAI-1. The plasminogen activator inhibitor (PAI)-1 level was 1,138 ± 26.3 ng/ml before direct hemoperfusion with an immobilized polymyxin B fiber column (DHP-PMX), but it was 67 ± 17.4 ng/ml at 24 hours after the start of treatment, 54 ± 13.6 ng/ml at 48 hours, and 52 ± 9.8 ng/ml at 72 hours, with statistically significant decreases from 48 hours onward compared with baseline (P < 0.05).
Figure 2
Figure 2
Changes in NE. The neutrophil elastase (NE) level was 443 ± 68.2 μg/l before direct hemoperfusion with an immobilized polymyxin B fiber column (DHP-PMX), but it was 366 ± 74.0 μg/l at 24 hours after the start of treatment, 274 ± 42.5 μg/l at 48 hours, and 249 ± 41.3 μg/l at 72 hours, with statistically significant decreases from 48 hours onward compared with baseline (P < 0.05).
Figure 3
Figure 3
Changes in IL-8. The IL-8 level was 54 ± 14.6 pg/ml before direct hemoperfusion with an immobilized polymyxin B fiber column (DHP-PMX), but it was 27 ± 7.5 pg/ml at 24 hours after the start of treatment, 19 ± 4.3 pg/ml at 48 hours after, and 20 ± 4.5 pg/ml at 72 hours after, with a statistically significant decrease from 48 hours onward compared with baseline (P < 0.05).
Figure 4
Figure 4
Changes in PaO2/FiO2 ratio. The arterial oxygen tension (PaO2)/fractional inspired oxygen (FiO2) ratio was 244 ± 26.3 before direct hemoperfusion with an immobilized polymyxin B fiber column (DHP-PMX). It increased to 274 ± 28.6 at 24 hours after the start of treatment, 289 ± 26.2 at 48 hours, 348 ± 46.0 at 72 hours, 322 ± 22.1 at 96 hours, and 352 ± 25.4 at 120 hours, with statistically significant improvement from 96 hours onward compared with baseline (P < 0.05).
Figure 5
Figure 5
Relationship between the PaO2/FiO2 ratio and NE. There was an inverse relationship between the arterial oxygen tension (PaO2)/fractional inspired oxygen (FiO2) ratio (P/F ratio) and peripheral blood neutrophil elastase (NE) level. The correlation coefficient between the log-transformed PaO2/FiO2 ratio and log-transformed NE value was -0.337 (P = 0.0198).
Figure 6
Figure 6
Relationship between the PaO2/FiO2 ratio and IL-8. There was an inverse relationship between the arterial oxygen tension (PaO2)/fractional inspired oxygen (FiO2) ratio (P/F ratio) and peripheral blood IL-8 level. The correlation coefficient between the log-transformed PaO2/FiO2 ratio and log-transformed IL-8 value was -0.417 (P = 0.0032).

Comment in

Similar articles

Cited by

References

    1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Conensus Conference Committee. American College of Chest Physicans/Society of Critical Care Medicine. Chest. 1992;101:1644–1655. - PubMed
    1. Zimmerman JE, Knaus WA, Wagner DP, Sun X, Hakim RB, Nystrom PO. A comparison of risks and outcome for patients with organ system failure: 1982-1990. Crit Care Med. 1996;24:1633–1641. doi: 10.1097/00003246-199610000-00006. - DOI - PubMed
    1. Ziegler EJ, Fisher CJ, Jnr, Sprung CL, Staraube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, et al. Treatment of gram-negative bacteremia and shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991;324:429–436. - PubMed
    1. Greenman RL, Schein RMH, Martin MA, Wenzel RP, Macintyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991;266:1097–1102. doi: 10.1001/jama.266.8.1097. - DOI - PubMed
    1. Quezado ZMN, Banks SM, Natanson C. New strategies for combating sepsis: the magic bullets missed the mark ... but the search continues. Trends Biotechnol. 1995;13:56–63. doi: 10.1016/S0167-7799(00)88906-4. - DOI - PubMed

MeSH terms